HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build
HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions
| Active as of 2022-10-28 |
<PlanDefinition xmlns="http://hl7.org/fhir">
<id value="60071000210106"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml" class="regimen-display">
<h1 title="Gynaecological Endometrial Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel">GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel</h1>
<ul class="regimen-tabs">
</ul>
<div>
<div class="regimen-tab-content overview-content active">
<h2 class="regimen-section-title">Treatment Overview</h2>
<div class="regimen-instructions html-instructions"><p>This regimen consists of two parts: cISplatin chemoradiation followed by cARBOplatin and PACLItaxel. </p><p>Do not confuse with the chemotherapy-only regimen: GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only].</p></div>
<div>
<div class="regimen-components">
<div class="regimen-component">
<a href="60071000210106/component/6c16faca-cb95-4db6-ab7d-433b4d991532|10" title="6c16faca-cb95-4db6-ab7d-433b4d991532|10" class="component-link">Part 1: cISplatin chemoradiation</a>
<div class="html-instructions"><p>Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy.</p></div>
</div>
<div class="regimen-component">
<a href="60071000210106/component/60f966e0-b24e-47fa-9e0c-d90abec4e58e|10" title="60f966e0-b24e-47fa-9e0c-d90abec4e58e|10" class="component-link">Part 2: cARBOplatin and PACLItaxel</a>
<div class="html-instructions"><p>Commence within 3 weeks after completion of radiation therapy.</p></div>
</div>
</div>
</div>
</div>
<div class="references">
<h2>Supportive Care Factors</h2>
<table>
<tr>
<th class="regimen-col-3">Factor</th>
<th class="regimen-col-4">Value</th>
</tr>
<tr>
<td class="regimen-col-3">Emetogenicity:</td>
<td class="regimen-col-4">High</td>
</tr>
<tr>
<td class="regimen-col-3">Growth factor support:</td>
<td class="regimen-col-4">Variable</td>
</tr>
<tr>
<td class="regimen-col-3">Hydration:</td>
<td class="regimen-col-4">Variable</td>
</tr>
<tr>
<td class="regimen-col-3">Hypersensitivity / Infusion related reaction risk:</td>
<td class="regimen-col-4">Variable</td>
</tr>
</table>
</div>
<div class="references">
<h2>References</h2>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/29449189" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/27397040" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/31345626" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/25089112" target="_blank">Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641., PMID: 25089112</a>
</small>
</p>
<p class="regimen-reference">
<small>Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021).</small>
</p>
<p class="regimen-reference">
<small>Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020).</small>
</p>
</div>
<div class="disclaimer">
<p><b>* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.</b></p>
</div>
</div>
</div>
</text>
<contained>
<PlanDefinition>
<id value="6c16faca-cb95-4db6-ab7d-433b4d991532|10"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml" class="regimen-display">
<h1 title="Gynaecological - cISplatin chemoradiation">Part 1: cISplatin chemoradiation (GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel)</h1>
<ul class="regimen-tabs">
</ul>
<div>
<div class="regimen-tab-content overview-content active">
<h2 class="regimen-section-title">Treatment Overview</h2>
<div class="regimen-instructions html-instructions"><p>Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy.</p></div>
<div>
<div id="overview-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237" title="Cycle 1" class="cycle-overview regimen-item">
<h2>
Cycle 1 - 28 days
</h2>
<div class="regimen-row">
<div class="regimen-col-3"><b>Cycle length:</b></div>
<div class="regimen-col-9">28</div>
</div>
</div>
</div>
</div>
<div class="regimen-tab-content cycle-details-content">
<h2 class="regimen-section-title">Cycle details</h2>
<div class="cycle-overview">
<h2>
Cycle 1 - 28 days
</h2>
<table>
<thead>
<tr>
<th class="regimen-col-3">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-3">Route</th>
<th class="regimen-col-2">Days</th>
<th class="regimen-col-2">Max Duration</th>
</tr>
</thead>
<tbody>
<tr id="cycle-details-content|Order-Set-1-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine" class="regimen-item">
<td class="regimen-col-3">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1 to 4, 22 to 25</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-2-9c5cbd06-e72c-459d-aa16-4de0cd66d84c" title="Cycle 1: aprepitant" class="regimen-item">
<td class="regimen-col-3">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">125 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1, 22</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-3-362ee8a4-0286-4a94-aaf3-0755a71148c7" title="Cycle 1: aprepitant" class="regimen-item">
<td class="regimen-col-3">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">80 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">2, 3, 23, 24</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-4-bdb1827c-e30c-4e46-b795-43428e5fbe7d" title="Cycle 1: dexamethasone" class="regimen-item">
<td class="regimen-col-3">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">12 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1, 22</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-5-b0748e33-9ce7-43b8-8d11-4d4d462d632d" title="Cycle 1: dexamethasone" class="regimen-item">
<td class="regimen-col-3">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">2, 3, 4, 23, 24, 25</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-6-1932db21-4019-4c52-a0f5-e3b41fa5ea90" title="Cycle 1: ondansetron" class="regimen-item">
<td class="regimen-col-3">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1, 22</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-7-839946c6-c6e5-439f-bf1d-bed24412733e" title="Cycle 1: magnesium sulfate heptahydrate" class="regimen-item">
<td class="regimen-col-3">
<span title="20020231000116101" class="medication is-supportive-care ">magnesium sulfate heptahydrate</span>
</td>
<td class="regimen-col-2 handle-lines">10 mmol</td>
<td class="regimen-col-3">intravenous</td>
<td class="regimen-col-2">1, 22</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
</tr>
<tr id="cycle-details-content|Order-Set-8-84d0cb30-0b0a-4189-9f6d-ed1a95c7596e" title="Cycle 1: cISplatin" class="regimen-item">
<td class="regimen-col-3">
<span title="10182171000116105" class="medication ">cISplatin</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">50 mg/m²</td>
<td class="regimen-col-3">intravenous</td>
<td class="regimen-col-2">1, 22</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
</tr>
<tr id="cycle-details-content|Order-Set-9-567c1f04-dd4b-477c-a52b-11894a454d20" title="Cycle 1: sodium chloride" class="regimen-item">
<td class="regimen-col-3">
<span title="10759231000116105" class="medication is-supportive-care ">sodium chloride</span>
</td>
<td class="regimen-col-2 handle-lines">0.9 %</td>
<td class="regimen-col-3">intravenous</td>
<td class="regimen-col-2">1, 22</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
</tr>
<tr id="cycle-details-content|Order-Set-10-4f29afa5-27c5-447e-bb32-144513dde9b2" title="Cycle 1: ondansetron" class="regimen-item">
<td class="regimen-col-3">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1, 22</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-11-95ea216d-cc89-499c-b742-7d8b149dcd8e" title="Cycle 1: cycliZINE" class="regimen-item">
<td class="regimen-col-3">
<span title="44123411000116107" class="medication is-supportive-care ">cycliZINE</span>
</td>
<td class="regimen-col-2 handle-lines">50 mg Three times daily</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="regimen-tab-content day-details-content">
<h2 class="regimen-section-title">Full details</h2>
<div class="cycle">
<div class="sticky">
<h2>
Cycle 1 - 28 days
</h2>
</div>
<div>
<div class="day-overview">
<h3>Day: 1</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. Some centres may choose to omit pre-chemotherapy dose or advise patient to take the night before chemotherapy if patient has to drive to appointment.
</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-9c5cbd06-e72c-459d-aa16-4de0cd66d84c" title="Cycle 1: aprepitant - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">125 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-bdb1827c-e30c-4e46-b795-43428e5fbe7d" title="Cycle 1: dexamethasone - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">12 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy with food.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-1932db21-4019-4c52-a0f5-e3b41fa5ea90" title="Cycle 1: ondansetron - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy.
</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-839946c6-c6e5-439f-bf1d-bed24412733e" title="Cycle 1: magnesium sulfate heptahydrate - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="20020231000116101" class="medication is-supportive-care ">magnesium sulfate heptahydrate</span>
</td>
<td class="regimen-col-2 handle-lines">10 mmol</td>
<td class="regimen-col-2">intravenous</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>In 1000 mL of sodium chloride 0.9%, prior to cISplatin infusion.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-84d0cb30-0b0a-4189-9f6d-ed1a95c7596e" title="Cycle 1: cISplatin - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10182171000116105" class="medication ">cISplatin</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">50 mg/m²</td>
<td class="regimen-col-2">intravenous</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>In 500 - 1000 mL of sodium chloride 0.9%, depending on stability. Ensure patient has passed urine as per institutional policy. Hypersensitivity risk increases with number of cycles of cISplatin.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-567c1f04-dd4b-477c-a52b-11894a454d20" title="Cycle 1: sodium chloride - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10759231000116105" class="medication is-supportive-care ">sodium chloride</span>
</td>
<td class="regimen-col-2 handle-lines">0.9 %</td>
<td class="regimen-col-2">intravenous</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
<td class="regimen-col-4">
<div><b>Quantity:</b>1000 mL</div>
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>After cISplatin infusion. If cISplatin is infused in 1000 mL, centres may choose to omit this bag of fluid.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-4f29afa5-27c5-447e-bb32-144513dde9b2" title="Cycle 1: ondansetron - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>EIGHT hours after chemotherapy OR before bed.
</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-1-95ea216d-cc89-499c-b742-7d8b149dcd8e" title="Cycle 1: cycliZINE - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="44123411000116107" class="medication is-supportive-care ">cycliZINE</span>
</td>
<td class="regimen-col-2 handle-lines">50 mg Three times daily</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>When required for nausea and/or vomiting.
Warning: may cause drowsiness. Consider starting dose at 25 mg and increasing as tolerated/required.
The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.
Note that domperidone is not recommended in combination with olanzapine and ondansetron due to potential risk of QT prolongation.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 2</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-2-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine - Day 2" class="regimen-item">
<td class="regimen-col-2">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-2-362ee8a4-0286-4a94-aaf3-0755a71148c7" title="Cycle 1: aprepitant - Day 2" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">80 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-2-b0748e33-9ce7-43b8-8d11-4d4d462d632d" title="Cycle 1: dexamethasone - Day 2" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 3</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-3-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine - Day 3" class="regimen-item">
<td class="regimen-col-2">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-3-362ee8a4-0286-4a94-aaf3-0755a71148c7" title="Cycle 1: aprepitant - Day 3" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">80 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-3-b0748e33-9ce7-43b8-8d11-4d4d462d632d" title="Cycle 1: dexamethasone - Day 3" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 4</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-4-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine - Day 4" class="regimen-item">
<td class="regimen-col-2">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-4-b0748e33-9ce7-43b8-8d11-4d4d462d632d" title="Cycle 1: dexamethasone - Day 4" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 22</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-22-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine - Day 22" class="regimen-item">
<td class="regimen-col-2">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. Some centres may choose to omit pre-chemotherapy dose or advise patient to take the night before chemotherapy if patient has to drive to appointment.
</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-22-9c5cbd06-e72c-459d-aa16-4de0cd66d84c" title="Cycle 1: aprepitant - Day 22" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">125 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-22-bdb1827c-e30c-4e46-b795-43428e5fbe7d" title="Cycle 1: dexamethasone - Day 22" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">12 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy with food.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-22-1932db21-4019-4c52-a0f5-e3b41fa5ea90" title="Cycle 1: ondansetron - Day 22" class="regimen-item">
<td class="regimen-col-2">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy.
</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-22-839946c6-c6e5-439f-bf1d-bed24412733e" title="Cycle 1: magnesium sulfate heptahydrate - Day 22" class="regimen-item">
<td class="regimen-col-2">
<span title="20020231000116101" class="medication is-supportive-care ">magnesium sulfate heptahydrate</span>
</td>
<td class="regimen-col-2 handle-lines">10 mmol</td>
<td class="regimen-col-2">intravenous</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>In 1000 mL of sodium chloride 0.9%, prior to cISplatin infusion.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-22-84d0cb30-0b0a-4189-9f6d-ed1a95c7596e" title="Cycle 1: cISplatin - Day 22" class="regimen-item">
<td class="regimen-col-2">
<span title="10182171000116105" class="medication ">cISplatin</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">50 mg/m²</td>
<td class="regimen-col-2">intravenous</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>In 500 - 1000 mL of sodium chloride 0.9%, depending on stability. Ensure patient has passed urine as per institutional policy. Hypersensitivity risk increases with number of cycles of cISplatin.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-22-567c1f04-dd4b-477c-a52b-11894a454d20" title="Cycle 1: sodium chloride - Day 22" class="regimen-item">
<td class="regimen-col-2">
<span title="10759231000116105" class="medication is-supportive-care ">sodium chloride</span>
</td>
<td class="regimen-col-2 handle-lines">0.9 %</td>
<td class="regimen-col-2">intravenous</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
<td class="regimen-col-4">
<div><b>Quantity:</b>1000 mL</div>
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>After cISplatin infusion. If cISplatin is infused in 1000 mL, centres may choose to omit this bag of fluid.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-22-4f29afa5-27c5-447e-bb32-144513dde9b2" title="Cycle 1: ondansetron - Day 22" class="regimen-item">
<td class="regimen-col-2">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>EIGHT hours after chemotherapy OR before bed.
</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 23</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-23-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine - Day 23" class="regimen-item">
<td class="regimen-col-2">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-23-362ee8a4-0286-4a94-aaf3-0755a71148c7" title="Cycle 1: aprepitant - Day 23" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">80 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-23-b0748e33-9ce7-43b8-8d11-4d4d462d632d" title="Cycle 1: dexamethasone - Day 23" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 24</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-24-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine - Day 24" class="regimen-item">
<td class="regimen-col-2">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-24-362ee8a4-0286-4a94-aaf3-0755a71148c7" title="Cycle 1: aprepitant - Day 24" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">80 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-24-b0748e33-9ce7-43b8-8d11-4d4d462d632d" title="Cycle 1: dexamethasone - Day 24" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 25</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-25-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9" title="Cycle 1: olanzapine - Day 25" class="regimen-item">
<td class="regimen-col-2">
<span title="10757201000116108" class="medication is-supportive-care ">olanzapine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.</div>
</td>
</tr>
<tr id="day-details-content|44ecb1b0-5f71-4757-a71d-89c9c1d89237-25-b0748e33-9ce7-43b8-8d11-4d4d462d632d" title="Cycle 1: dexamethasone - Day 25" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion.</div>
</td>
</tr>
</table>
</div>
</div>
</div>
</div>
<div class="references">
<h2>Supportive Care Factors</h2>
<table>
<tr>
<th class="regimen-col-3">Factor</th>
<th class="regimen-col-4">Value</th>
</tr>
<tr>
<td class="regimen-col-3">Emetogenicity:</td>
<td class="regimen-col-4">High</td>
</tr>
<tr>
<td class="regimen-col-3">Hydration:</td>
<td class="regimen-col-4">Routine hydration recommended</td>
</tr>
</table>
</div>
<div class="references">
<h2>References</h2>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/29449189" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/27397040" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/31345626" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/25089112" target="_blank">Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641., PMID: 25089112</a>
</small>
</p>
<p class="regimen-reference">
<small>Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021).</small>
</p>
</div>
<div class="disclaimer">
<p><b>* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.</b></p>
</div>
</div>
</div>
</text>
<contained>
<ActivityDefinition>
<id value="8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_8d1a1395_eaa2_4ef0_9a91_c8ed3cdd25d9"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10757201000116108"/>
<display value="olanzapine"/>
</coding>
<text value="olanzapine"/>
</productCodeableConcept>
<dosage>
<text value="5 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="5"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="9c5cbd06-e72c-459d-aa16-4de0cd66d84c"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_9c5cbd06_e72c_459d_aa16_4de0cd66d84c"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10224481000116104"/>
<display value="aprepitant"/>
</coding>
<text value="aprepitant"/>
</productCodeableConcept>
<dosage>
<text value="125 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="125"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="362ee8a4-0286-4a94-aaf3-0755a71148c7"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_362ee8a4_0286_4a94_aaf3_0755a71148c7"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10224481000116104"/>
<display value="aprepitant"/>
</coding>
<text value="aprepitant"/>
</productCodeableConcept>
<dosage>
<text value="80 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="80"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="bdb1827c-e30c-4e46-b795-43428e5fbe7d"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_bdb1827c_e30c_4e46_b795_43428e5fbe7d"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10238921000116102"/>
<display value="dexamethasone"/>
</coding>
<text value="dexamethasone"/>
</productCodeableConcept>
<dosage>
<text value="12 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="12"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="b0748e33-9ce7-43b8-8d11-4d4d462d632d"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_b0748e33_9ce7_43b8_8d11_4d4d462d632d"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10238921000116102"/>
<display value="dexamethasone"/>
</coding>
<text value="dexamethasone"/>
</productCodeableConcept>
<dosage>
<text value="8 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="8"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="1932db21-4019-4c52-a0f5-e3b41fa5ea90"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_1932db21_4019_4c52_a0f5_e3b41fa5ea90"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10497011000116104"/>
<display value="ondansetron"/>
</coding>
<text value="ondansetron"/>
</productCodeableConcept>
<dosage>
<text value="8 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="8"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="839946c6-c6e5-439f-bf1d-bed24412733e"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_839946c6_c6e5_439f_bf1d_bed24412733e"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="20020231000116101"/>
<display value="magnesium sulfate heptahydrate"/>
</coding>
<text value="magnesium sulfate heptahydrate"/>
</productCodeableConcept>
<dosage>
<text value="10 mmol over 60 minutes by intravenous"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386358000"/>
</coding>
<text value="intravenous"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="10"/>
<unit value="mmol"/>
<system value="http://snomed.info/sct"/>
<code value="258718000"/>
</doseQuantity>
<rateRange>
<high>
<value value="60"/>
<unit value="Min"/>
<system value="http://unitsofmeasure.org"/>
</high>
</rateRange>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="84d0cb30-0b0a-4189-9f6d-ed1a95c7596e"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_84d0cb30_0b0a_4189_9f6d_ed1a95c7596e"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10182171000116105"/>
<display value="cISplatin"/>
</coding>
<text value="cISplatin"/>
</productCodeableConcept>
<dosage>
<text value="50 mg/m² over 60 minutes by intravenous"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386358000"/>
</coding>
<text value="intravenous"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="50"/>
<unit value="mg/m²"/>
<system value="http://snomed.info/sct"/>
<code value="404216004"/>
</doseQuantity>
<rateRange>
<high>
<value value="60"/>
<unit value="Min"/>
<system value="http://unitsofmeasure.org"/>
</high>
</rateRange>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="567c1f04-dd4b-477c-a52b-11894a454d20"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_567c1f04_dd4b_477c_a52b_11894a454d20"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10759231000116105"/>
<display value="sodium chloride"/>
</coding>
<text value="sodium chloride"/>
</productCodeableConcept>
<quantity>
<value value="1000"/>
<unit value="mL"/>
<system value="http://snomed.info/sct"/>
<code value="258773002"/>
</quantity>
<dosage>
<text value="0.9 % over 60 minutes by intravenous"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386358000"/>
</coding>
<text value="intravenous"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="0.9"/>
<unit value="%"/>
<system value="http://snomed.info/sct"/>
<code value="118582008"/>
</doseQuantity>
<rateRange>
<high>
<value value="60"/>
<unit value="Min"/>
<system value="http://unitsofmeasure.org"/>
</high>
</rateRange>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="4f29afa5-27c5-447e-bb32-144513dde9b2"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_4f29afa5_27c5_447e_bb32_144513dde9b2"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10497011000116104"/>
<display value="ondansetron"/>
</coding>
<text value="ondansetron"/>
</productCodeableConcept>
<dosage>
<text value="8 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="8"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="95ea216d-cc89-499c-b742-7d8b149dcd8e"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_95ea216d_cc89_499c_b742_7d8b149dcd8e"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="44123411000116107"/>
<display value="cycliZINE"/>
</coding>
<text value="cycliZINE"/>
</productCodeableConcept>
<dosage>
<text value="50 mg Three times daily by oral administration"/>
<timing>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="229798009"/>
</coding>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/v3-GTSAbbreviation"/>
<code value="TID"/>
</coding>
<text value="Three times daily"/>
</code>
</timing>
<asNeededBoolean value="true"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="50"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions">
<valueMarkdown
value="<p>Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy.</p>"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer">
<valueMarkdown
value="The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval."/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="419219000"/>
</coding>
<text value="Emetogenicity"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="75540009"/>
</coding>
<text value="High"/>
</valueCodeableConcept>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="281800008"/>
</coding>
<text value="Hydration"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="54261000210107"/>
</coding>
<text value="Routine hydration recommended"/>
</valueCodeableConcept>
</extension>
</extension>
<url
value="https://fhir.nzf.org.nz/fhir/PlanDefinition/51b725b5-05a8-4890-b8f6-044b641eb61f"/>
<identifier>
<system value="CUSTOM"/>
<value value="51b725b5-05a8-4890-b8f6-044b641eb61f"/>
</identifier>
<version value="0.0.5"/>
<name value="GYN - cISplatin chemoradiation"/>
<title
value="Part 1: cISplatin chemoradiation (GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel)"/>
<subtitle value="Gynaecological - cISplatin chemoradiation"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/>
<code value="clinical-protocol"/>
</coding>
</type>
<status value="active"/>
<date value="2022-10-13"/>
<publisher value="New Zealand Medicines Formulary LP"/>
<description
value="A drug treatment regimen for Gynaecological - cISplatin chemoradiation"/>
<useContext>
<code>
<system
value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
<code value="focus"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="310789003"/>
</coding>
<text value="Gynaecological"/>
</valueCodeableConcept>
</useContext>
<copyright value="All rights reserved."/>
<author>
<name value="New Zealand Medicines Formulary LP"/>
</author>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/29449189"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/29449189"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/27397040"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/27397040"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/31345626"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/31345626"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641., PMID: 25089112"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/25089112"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/25089112"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021)."/>
</relatedArtifact>
<action id="44ecb1b0-5f71-4757-a71d-89c9c1d89237">
<prefix value="1"/>
<description value="Cycle 1 - 28 days"/>
<timingTiming>
<repeat>
<count value="1"/>
<duration value="28"/>
<durationUnit value="d"/>
</repeat>
</timingTiming>
<selectionBehavior value="all"/>
<action id="Order-Set-1-8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONE hour prior to chemotherapy. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. Some centres may choose to omit pre-chemotherapy dose or advise patient to take the night before chemotherapy if patient has to drive to appointment."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="2"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="3"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="4"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="22"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONE hour prior to chemotherapy. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. Some centres may choose to omit pre-chemotherapy dose or advise patient to take the night before chemotherapy if patient has to drive to appointment."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="23"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="24"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="25"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake."/>
</extension>
</extension>
<definitionCanonical value="#8d1a1395-eaa2-4ef0-9a91-c8ed3cdd25d9"/>
</action>
<action id="Order-Set-2-9c5cbd06-e72c-459d-aa16-4de0cd66d84c">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONE hour prior to chemotherapy."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="22"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONE hour prior to chemotherapy."/>
</extension>
</extension>
<definitionCanonical value="#9c5cbd06-e72c-459d-aa16-4de0cd66d84c"/>
</action>
<action id="Order-Set-3-362ee8a4-0286-4a94-aaf3-0755a71148c7">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="2"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONCE daily in the morning."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="3"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONCE daily in the morning."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="23"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONCE daily in the morning."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="24"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONCE daily in the morning."/>
</extension>
</extension>
<definitionCanonical value="#362ee8a4-0286-4a94-aaf3-0755a71148c7"/>
</action>
<action id="Order-Set-4-bdb1827c-e30c-4e46-b795-43428e5fbe7d">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONE hour prior to chemotherapy with food."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="22"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONE hour prior to chemotherapy with food."/>
</extension>
</extension>
<definitionCanonical value="#bdb1827c-e30c-4e46-b795-43428e5fbe7d"/>
</action>
<action id="Order-Set-5-b0748e33-9ce7-43b8-8d11-4d4d462d632d">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="2"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="3"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="4"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="23"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="24"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="25"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion."/>
</extension>
</extension>
<definitionCanonical value="#b0748e33-9ce7-43b8-8d11-4d4d462d632d"/>
</action>
<action id="Order-Set-6-1932db21-4019-4c52-a0f5-e3b41fa5ea90">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONE hour prior to chemotherapy."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="22"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONE hour prior to chemotherapy."/>
</extension>
</extension>
<definitionCanonical value="#1932db21-4019-4c52-a0f5-e3b41fa5ea90"/>
</action>
<action id="Order-Set-7-839946c6-c6e5-439f-bf1d-bed24412733e">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="In 1000 mL of sodium chloride 0.9%, prior to cISplatin infusion."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="22"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="In 1000 mL of sodium chloride 0.9%, prior to cISplatin infusion."/>
</extension>
</extension>
<definitionCanonical value="#839946c6-c6e5-439f-bf1d-bed24412733e"/>
</action>
<action id="Order-Set-8-84d0cb30-0b0a-4189-9f6d-ed1a95c7596e">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="In 500 - 1000 mL of sodium chloride 0.9%, depending on stability. Ensure patient has passed urine as per institutional policy. Hypersensitivity risk increases with number of cycles of cISplatin."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="22"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="In 500 - 1000 mL of sodium chloride 0.9%, depending on stability. Ensure patient has passed urine as per institutional policy. Hypersensitivity risk increases with number of cycles of cISplatin."/>
</extension>
</extension>
<definitionCanonical value="#84d0cb30-0b0a-4189-9f6d-ed1a95c7596e"/>
</action>
<action id="Order-Set-9-567c1f04-dd4b-477c-a52b-11894a454d20">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="After cISplatin infusion. If cISplatin is infused in 1000 mL, centres may choose to omit this bag of fluid."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="22"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="After cISplatin infusion. If cISplatin is infused in 1000 mL, centres may choose to omit this bag of fluid."/>
</extension>
</extension>
<definitionCanonical value="#567c1f04-dd4b-477c-a52b-11894a454d20"/>
</action>
<action id="Order-Set-10-4f29afa5-27c5-447e-bb32-144513dde9b2">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="EIGHT hours after chemotherapy OR before bed."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="22"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="EIGHT hours after chemotherapy OR before bed."/>
</extension>
</extension>
<definitionCanonical value="#4f29afa5-27c5-447e-bb32-144513dde9b2"/>
</action>
<action id="Order-Set-11-95ea216d-cc89-499c-b742-7d8b149dcd8e">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="When required for nausea and/or vomiting.
Warning: may cause drowsiness. Consider starting dose at 25 mg and increasing as tolerated/required.
The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.
Note that domperidone is not recommended in combination with olanzapine and ondansetron due to potential risk of QT prolongation."/>
</extension>
</extension>
<definitionCanonical value="#95ea216d-cc89-499c-b742-7d8b149dcd8e"/>
</action>
</action>
</PlanDefinition>
</contained>
<contained>
<PlanDefinition>
<id value="60f966e0-b24e-47fa-9e0c-d90abec4e58e|10"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml" class="regimen-display">
<h1 title="Gynaecological - cARBOplatin and PACLItaxel [following chemoradiation]">Part 2: cARBOplatin and PACLItaxel (GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel)</h1>
<ul class="regimen-tabs">
</ul>
<div>
<div class="regimen-tab-content overview-content active">
<h2 class="regimen-section-title">Treatment Overview</h2>
<div class="regimen-instructions html-instructions"><p>Commence within 3 weeks after completion of radiation therapy.</p><p><br/></p><p>This regimen follows cISplatin chemoradiation, not to be confused with GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only].</p></div>
<div>
<div id="overview-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd" title="Cycle 1" class="cycle-overview regimen-item">
<h2>
Cycles 1 to 4 - 21 days
</h2>
<div class="regimen-row">
<div class="regimen-col-3"><b>Cycle length:</b></div>
<div class="regimen-col-9">21</div>
</div>
</div>
</div>
</div>
<div class="regimen-tab-content cycle-details-content">
<h2 class="regimen-section-title">Cycle details</h2>
<div class="cycle-overview">
<h2>
Cycles 1 to 4 - 21 days
</h2>
<table>
<thead>
<tr>
<th class="regimen-col-3">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-3">Route</th>
<th class="regimen-col-2">Days</th>
<th class="regimen-col-2">Max Duration</th>
</tr>
</thead>
<tbody>
<tr id="cycle-details-content|Order-Set-1-735bf518-d4c8-4745-95ba-ee1b9a2ac2a5" title="Cycle 1: dexamethasone" class="regimen-item">
<td class="regimen-col-3">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">20 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">0</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-2-4525e318-7932-4b80-80c9-c6d050a0081a" title="Cycle 1: aprepitant" class="regimen-item">
<td class="regimen-col-3">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">125 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-3-a79c6e28-16a6-4092-9f29-a3fec151e24a" title="Cycle 1: aprepitant" class="regimen-item">
<td class="regimen-col-3">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">80 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">2, 3</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-4-fed4f806-9fce-4e58-8a28-42bfaa5127f3" title="Cycle 1: dexamethasone" class="regimen-item">
<td class="regimen-col-3">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">12 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-5-07e776e7-e53a-46bc-bdcb-0593f30fc551" title="Cycle 1: dexamethasone" class="regimen-item">
<td class="regimen-col-3">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">2, 3</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-6-51cfa87d-259f-4664-8fac-afdb16632d87" title="Cycle 1: ondansetron" class="regimen-item">
<td class="regimen-col-3">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-7-2560dbcf-dd74-4323-826a-365b674a62cb" title="Cycle 1: loratadine" class="regimen-item">
<td class="regimen-col-3">
<span title="10056971000116105" class="medication is-supportive-care ">loratadine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">10 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-8-181decef-3c7b-448d-baf2-9de3d688bbae" title="Cycle 1: famotidine" class="regimen-item">
<td class="regimen-col-3">
<span title="10055201000116102" class="medication is-supportive-care ">famotidine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">20 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-9-34f8692c-274f-4576-9153-4f52284dd404" title="Cycle 1: PACLItaxel" class="regimen-item">
<td class="regimen-col-3">
<span title="10050001000116101" class="medication ">PACLItaxel</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">175 mg/m²</td>
<td class="regimen-col-3">intravenous</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines">3 hours</td>
</tr>
<tr id="cycle-details-content|Order-Set-10-792aaaf8-d843-4f2c-bd2b-7250961b2454" title="Cycle 1: cARBOplatin" class="regimen-item">
<td class="regimen-col-3">
<span title="10147121000116104" class="medication ">cARBOplatin</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 AUC (area under the curve)</td>
<td class="regimen-col-3">intravenous</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
</tr>
<tr id="cycle-details-content|Order-Set-11-9d47b655-4d83-448a-9a36-cf3bff1917c7" title="Cycle 1: ondansetron" class="regimen-item">
<td class="regimen-col-3">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
<tr id="cycle-details-content|Order-Set-12-a922a58f-c297-4fd1-b752-5ac18250095f" title="Cycle 1: domperidone" class="regimen-item">
<td class="regimen-col-3">
<span title="10472211000116103" class="medication is-supportive-care ">domperidone</span>
</td>
<td class="regimen-col-2 handle-lines">10 mg Three times daily</td>
<td class="regimen-col-3">oral administration</td>
<td class="regimen-col-2">1</td>
<td class="regimen-col-2 handle-lines"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="regimen-tab-content day-details-content">
<h2 class="regimen-section-title">Full details</h2>
<div class="cycle">
<div class="sticky">
<h2>
Cycles 1 to 4 - 21 days
</h2>
</div>
<div>
<div class="day-overview">
<h3>Day: 0</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-0-735bf518-d4c8-4745-95ba-ee1b9a2ac2a5" title="Cycle 1: dexamethasone - Day 0" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">20 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>Take the night prior to PACLItaxel infusion with food. If the initial infusion(s) of PACLItaxel are well tolerated, clinicians may decide at their discretion, to omit this dose.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 1</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-4525e318-7932-4b80-80c9-c6d050a0081a" title="Cycle 1: aprepitant - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">125 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy.</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-fed4f806-9fce-4e58-8a28-42bfaa5127f3" title="Cycle 1: dexamethasone - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">12 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy with food. </div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-51cfa87d-259f-4664-8fac-afdb16632d87" title="Cycle 1: ondansetron - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to chemotherapy.</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-2560dbcf-dd74-4323-826a-365b674a62cb" title="Cycle 1: loratadine - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10056971000116105" class="medication is-supportive-care ">loratadine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">10 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to PACLItaxel infusion.
</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-181decef-3c7b-448d-baf2-9de3d688bbae" title="Cycle 1: famotidine - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10055201000116102" class="medication is-supportive-care ">famotidine</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">20 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-34f8692c-274f-4576-9153-4f52284dd404" title="Cycle 1: PACLItaxel - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10050001000116101" class="medication ">PACLItaxel</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">175 mg/m²</td>
<td class="regimen-col-2">intravenous</td>
<td class="regimen-col-2 handle-lines">3 hours</td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size.
Please carry out graded challenge as per institutional policy.</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-792aaaf8-d843-4f2c-bd2b-7250961b2454" title="Cycle 1: cARBOplatin - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10147121000116104" class="medication ">cARBOplatin</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">5 AUC (area under the curve)</td>
<td class="regimen-col-2">intravenous</td>
<td class="regimen-col-2 handle-lines">60 minutes</td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>Hypersensitivity risk increases with number of cycles of cARBOplatin.</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-9d47b655-4d83-448a-9a36-cf3bff1917c7" title="Cycle 1: ondansetron - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10497011000116104" class="medication is-supportive-care ">ondansetron</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>EIGHT hours after chemotherapy OR before bed.
</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-1-a922a58f-c297-4fd1-b752-5ac18250095f" title="Cycle 1: domperidone - Day 1" class="regimen-item">
<td class="regimen-col-2">
<span title="10472211000116103" class="medication is-supportive-care ">domperidone</span>
</td>
<td class="regimen-col-2 handle-lines">10 mg Three times daily</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>When required for nausea and/or vomiting.
The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 2</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-2-a79c6e28-16a6-4092-9f29-a3fec151e24a" title="Cycle 1: aprepitant - Day 2" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">80 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning.</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-2-07e776e7-e53a-46bc-bdcb-0593f30fc551" title="Cycle 1: dexamethasone - Day 2" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion.</div>
</td>
</tr>
</table>
</div>
<div class="day-overview">
<h3>Day: 3</h3>
<table>
<tr>
<th class="regimen-col-2">Medication</th>
<th class="regimen-col-2">Dose</th>
<th class="regimen-col-2">Route</th>
<th class="regimen-col-2">Max duration</th>
<th class="regimen-col-4">Details</th>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-3-a79c6e28-16a6-4092-9f29-a3fec151e24a" title="Cycle 1: aprepitant - Day 3" class="regimen-item">
<td class="regimen-col-2">
<span title="10224481000116104" class="medication is-supportive-care ">aprepitant</span>
</td>
<td class="regimen-col-2 handle-lines">80 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning.</div>
</td>
</tr>
<tr id="day-details-content|efd5b14c-23d1-4e7e-bd42-1de44cde08cd-3-07e776e7-e53a-46bc-bdcb-0593f30fc551" title="Cycle 1: dexamethasone - Day 3" class="regimen-item">
<td class="regimen-col-2">
<span title="10238921000116102" class="medication is-supportive-care ">dexamethasone</span>
<span>*</span>
</td>
<td class="regimen-col-2 handle-lines">8 mg</td>
<td class="regimen-col-2">oral administration</td>
<td class="regimen-col-2 handle-lines"></td>
<td class="regimen-col-4">
<div class="regimen-instructions html-instructions"><b>Instructions:</b><br/>ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion.</div>
</td>
</tr>
</table>
</div>
</div>
</div>
</div>
<div class="references">
<h2>Supportive Care Factors</h2>
<table>
<tr>
<th class="regimen-col-3">Factor</th>
<th class="regimen-col-4">Value</th>
</tr>
<tr>
<td class="regimen-col-3">Emetogenicity:</td>
<td class="regimen-col-4">High</td>
</tr>
<tr>
<td class="regimen-col-3">Growth factor support:</td>
<td class="regimen-col-4">Recommended for secondary prophylaxis</td>
</tr>
<tr>
<td class="regimen-col-3">Hypersensitivity / Infusion related reaction risk:</td>
<td class="regimen-col-4">High - routine premedication recommended</td>
</tr>
</table>
</div>
<div class="references">
<h2>References</h2>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/29449189" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/27397040" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/31345626" target="_blank">de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626</a>
</small>
</p>
<p class="regimen-reference">
<small>
<a href="https://pubmed.ncbi.nlm.nih.gov/25089112" target="_blank">Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641. , PMID: 25089112</a>
</small>
</p>
<p class="regimen-reference">
<small>Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021).</small>
</p>
<p class="regimen-reference">
<small>Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020).</small>
</p>
</div>
<div class="disclaimer">
<p><b>* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.</b></p>
</div>
</div>
</div>
</text>
<contained>
<ActivityDefinition>
<id value="735bf518-d4c8-4745-95ba-ee1b9a2ac2a5"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_735bf518_d4c8_4745_95ba_ee1b9a2ac2a5"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10238921000116102"/>
<display value="dexamethasone"/>
</coding>
<text value="dexamethasone"/>
</productCodeableConcept>
<dosage>
<text value="20 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="20"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="4525e318-7932-4b80-80c9-c6d050a0081a"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_4525e318_7932_4b80_80c9_c6d050a0081a"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10224481000116104"/>
<display value="aprepitant"/>
</coding>
<text value="aprepitant"/>
</productCodeableConcept>
<dosage>
<text value="125 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="125"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="a79c6e28-16a6-4092-9f29-a3fec151e24a"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_a79c6e28_16a6_4092_9f29_a3fec151e24a"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10224481000116104"/>
<display value="aprepitant"/>
</coding>
<text value="aprepitant"/>
</productCodeableConcept>
<dosage>
<text value="80 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="80"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="fed4f806-9fce-4e58-8a28-42bfaa5127f3"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_fed4f806_9fce_4e58_8a28_42bfaa5127f3"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10238921000116102"/>
<display value="dexamethasone"/>
</coding>
<text value="dexamethasone"/>
</productCodeableConcept>
<dosage>
<text value="12 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="12"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="07e776e7-e53a-46bc-bdcb-0593f30fc551"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_07e776e7_e53a_46bc_bdcb_0593f30fc551"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10238921000116102"/>
<display value="dexamethasone"/>
</coding>
<text value="dexamethasone"/>
</productCodeableConcept>
<dosage>
<text value="8 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="8"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="51cfa87d-259f-4664-8fac-afdb16632d87"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_51cfa87d_259f_4664_8fac_afdb16632d87"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10497011000116104"/>
<display value="ondansetron"/>
</coding>
<text value="ondansetron"/>
</productCodeableConcept>
<dosage>
<text value="8 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="8"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="2560dbcf-dd74-4323-826a-365b674a62cb"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_2560dbcf_dd74_4323_826a_365b674a62cb"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10056971000116105"/>
<display value="loratadine"/>
</coding>
<text value="loratadine"/>
</productCodeableConcept>
<dosage>
<text value="10 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="10"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="181decef-3c7b-448d-baf2-9de3d688bbae"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_181decef_3c7b_448d_baf2_9de3d688bbae"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10055201000116102"/>
<display value="famotidine"/>
</coding>
<text value="famotidine"/>
</productCodeableConcept>
<dosage>
<text value="20 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="20"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="34f8692c-274f-4576-9153-4f52284dd404"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_34f8692c_274f_4576_9153_4f52284dd404"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10050001000116101"/>
<display value="PACLItaxel"/>
</coding>
<text value="PACLItaxel"/>
</productCodeableConcept>
<dosage>
<text value="175 mg/m² over 3 hours by intravenous"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386358000"/>
</coding>
<text value="intravenous"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="175"/>
<unit value="mg/m²"/>
<system value="http://snomed.info/sct"/>
<code value="404216004"/>
</doseQuantity>
<rateRange>
<high>
<value value="3"/>
<unit value="H"/>
<system value="http://unitsofmeasure.org"/>
</high>
</rateRange>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="792aaaf8-d843-4f2c-bd2b-7250961b2454"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_792aaaf8_d843_4f2c_bd2b_7250961b2454"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10147121000116104"/>
<display value="cARBOplatin"/>
</coding>
<text value="cARBOplatin"/>
</productCodeableConcept>
<dosage>
<text
value="5 AUC (area under the curve) over 60 minutes by intravenous"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386358000"/>
</coding>
<text value="intravenous"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="5"/>
<unit value="AUC (area under the curve)"/>
<system value="http://snomed.info/sct"/>
<code value="413573002"/>
</doseQuantity>
<rateRange>
<high>
<value value="60"/>
<unit value="Min"/>
<system value="http://unitsofmeasure.org"/>
</high>
</rateRange>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="9d47b655-4d83-448a-9a36-cf3bff1917c7"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_9d47b655_4d83_448a_9a36_cf3bff1917c7"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10497011000116104"/>
<display value="ondansetron"/>
</coding>
<text value="ondansetron"/>
</productCodeableConcept>
<dosage>
<text value="8 mg by oral administration"/>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="8"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<contained>
<ActivityDefinition>
<id value="a922a58f-c297-4fd1-b752-5ac18250095f"/>
<meta>
<profile
value="http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"/>
</meta>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-off-label">
<valueBoolean value="false"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care">
<valueBoolean value="true"/>
</extension>
<name value="Orderset_a922a58f_c297_4fd1_b752_5ac18250095f"/>
<status value="active"/>
<productCodeableConcept>
<coding>
<system value="http://nzmt.org.nz"/>
<code value="10472211000116103"/>
<display value="domperidone"/>
</coding>
<text value="domperidone"/>
</productCodeableConcept>
<dosage>
<text value="10 mg Three times daily by oral administration"/>
<timing>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="229798009"/>
</coding>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/v3-GTSAbbreviation"/>
<code value="TID"/>
</coding>
<text value="Three times daily"/>
</code>
</timing>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="386359008"/>
</coding>
<text value="oral administration"/>
</route>
<doseAndRate>
<doseQuantity>
<value value="10"/>
<unit value="mg"/>
<system value="http://snomed.info/sct"/>
<code value="258684004"/>
</doseQuantity>
</doseAndRate>
</dosage>
</ActivityDefinition>
</contained>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions">
<valueMarkdown
value="<p>Commence within 3 weeks after completion of radiation therapy.</p><p><br/></p><p>This regimen follows cISplatin chemoradiation, not to be confused with GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only].</p>"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer">
<valueMarkdown
value="The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval."/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="419219000"/>
</coding>
<text value="Emetogenicity"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="75540009"/>
</coding>
<text value="High"/>
</valueCodeableConcept>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="81286007"/>
</coding>
<text value="Growth factor support"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="54371000210105"/>
</coding>
<text value="Recommended for secondary prophylaxis"/>
</valueCodeableConcept>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="421961002"/>
</coding>
<text value="Hypersensitivity / Infusion related reaction risk"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="723509005"/>
</coding>
<text value="High - routine premedication recommended"/>
</valueCodeableConcept>
</extension>
</extension>
<url
value="https://fhir.nzf.org.nz/fhir/PlanDefinition/feac2d6f-48bd-4fae-8cd1-8cff488859f9"/>
<identifier>
<system value="CUSTOM"/>
<value value="feac2d6f-48bd-4fae-8cd1-8cff488859f9"/>
</identifier>
<version value="0.0.4"/>
<name
value="GYN - cARBOplatin and PACLItaxel [following chemoradiation]"/>
<title
value="Part 2: cARBOplatin and PACLItaxel (GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel)"/>
<subtitle
value="Gynaecological - cARBOplatin and PACLItaxel [following chemoradiation]"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/>
<code value="clinical-protocol"/>
</coding>
</type>
<status value="active"/>
<date value="2022-10-13"/>
<publisher value="New Zealand Medicines Formulary LP"/>
<description
value="A drug treatment regimen for Gynaecological - cARBOplatin and PACLItaxel [following chemoradiation]"/>
<useContext>
<code>
<system
value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
<code value="focus"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="310789003"/>
</coding>
<text value="Gynaecological"/>
</valueCodeableConcept>
</useContext>
<copyright value="All rights reserved."/>
<author>
<name value="New Zealand Medicines Formulary LP"/>
</author>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/29449189"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/29449189"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/27397040"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/27397040"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/31345626"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/31345626"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641. , PMID: 25089112"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/25089112"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/25089112"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021)."/>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020)."/>
</relatedArtifact>
<action id="efd5b14c-23d1-4e7e-bd42-1de44cde08cd">
<prefix value="1"/>
<description value="Cycles 1 to 4 - 21 days"/>
<timingTiming>
<repeat>
<count value="4"/>
<duration value="21"/>
<durationUnit value="d"/>
</repeat>
</timingTiming>
<selectionBehavior value="all"/>
<action id="Order-Set-1-735bf518-d4c8-4745-95ba-ee1b9a2ac2a5">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="0"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="Take the night prior to PACLItaxel infusion with food. If the initial infusion(s) of PACLItaxel are well tolerated, clinicians may decide at their discretion, to omit this dose."/>
</extension>
</extension>
<definitionCanonical value="#735bf518-d4c8-4745-95ba-ee1b9a2ac2a5"/>
</action>
<action id="Order-Set-2-4525e318-7932-4b80-80c9-c6d050a0081a">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONE hour prior to chemotherapy."/>
</extension>
</extension>
<definitionCanonical value="#4525e318-7932-4b80-80c9-c6d050a0081a"/>
</action>
<action id="Order-Set-3-a79c6e28-16a6-4092-9f29-a3fec151e24a">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="2"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONCE daily in the morning."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="3"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONCE daily in the morning."/>
</extension>
</extension>
<definitionCanonical value="#a79c6e28-16a6-4092-9f29-a3fec151e24a"/>
</action>
<action id="Order-Set-4-fed4f806-9fce-4e58-8a28-42bfaa5127f3">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONE hour prior to chemotherapy with food."/>
</extension>
</extension>
<definitionCanonical value="#fed4f806-9fce-4e58-8a28-42bfaa5127f3"/>
</action>
<action id="Order-Set-5-07e776e7-e53a-46bc-bdcb-0593f30fc551">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="2"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion."/>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="3"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONCE daily in the morning with food.
Dose and duration may be individualised at clinician’s discretion."/>
</extension>
</extension>
<definitionCanonical value="#07e776e7-e53a-46bc-bdcb-0593f30fc551"/>
</action>
<action id="Order-Set-6-51cfa87d-259f-4664-8fac-afdb16632d87">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONE hour prior to chemotherapy."/>
</extension>
</extension>
<definitionCanonical value="#51cfa87d-259f-4664-8fac-afdb16632d87"/>
</action>
<action id="Order-Set-7-2560dbcf-dd74-4323-826a-365b674a62cb">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown value="ONE hour prior to PACLItaxel infusion."/>
</extension>
</extension>
<definitionCanonical value="#2560dbcf-dd74-4323-826a-365b674a62cb"/>
</action>
<action id="Order-Set-8-181decef-3c7b-448d-baf2-9de3d688bbae">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine."/>
</extension>
</extension>
<definitionCanonical value="#181decef-3c7b-448d-baf2-9de3d688bbae"/>
</action>
<action id="Order-Set-9-34f8692c-274f-4576-9153-4f52284dd404">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size.
Please carry out graded challenge as per institutional policy."/>
</extension>
</extension>
<definitionCanonical value="#34f8692c-274f-4576-9153-4f52284dd404"/>
</action>
<action id="Order-Set-10-792aaaf8-d843-4f2c-bd2b-7250961b2454">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="Hypersensitivity risk increases with number of cycles of cARBOplatin."/>
</extension>
</extension>
<definitionCanonical value="#792aaaf8-d843-4f2c-bd2b-7250961b2454"/>
</action>
<action id="Order-Set-11-9d47b655-4d83-448a-9a36-cf3bff1917c7">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="EIGHT hours after chemotherapy OR before bed."/>
</extension>
</extension>
<definitionCanonical value="#9d47b655-4d83-448a-9a36-cf3bff1917c7"/>
</action>
<action id="Order-Set-12-a922a58f-c297-4fd1-b752-5ac18250095f">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days">
<extension url="day">
<valueInteger value="1"/>
</extension>
<extension url="instructions">
<valueMarkdown
value="When required for nausea and/or vomiting.
The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics."/>
</extension>
</extension>
<definitionCanonical value="#a922a58f-c297-4fd1-b752-5ac18250095f"/>
</action>
</action>
</PlanDefinition>
</contained>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-treatment-setting">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="373846009"/>
</coding>
<text value="Adjuvant"/>
</valueCodeableConcept>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions">
<valueMarkdown
value="<p>This regimen consists of two parts: cISplatin chemoradiation followed by cARBOplatin and PACLItaxel. </p><p>Do not confuse with the chemotherapy-only regimen: GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only].</p>"/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer">
<valueMarkdown
value="The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval."/>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="419219000"/>
</coding>
<text value="Emetogenicity"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="75540009"/>
</coding>
<text value="High"/>
</valueCodeableConcept>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="81286007"/>
</coding>
<text value="Growth factor support"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="255372005"/>
</coding>
<text value="Variable"/>
</valueCodeableConcept>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="281800008"/>
</coding>
<text value="Hydration"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="255372005"/>
</coding>
<text value="Variable"/>
</valueCodeableConcept>
</extension>
</extension>
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor">
<extension url="factor">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="421961002"/>
</coding>
<text value="Hypersensitivity / Infusion related reaction risk"/>
</valueCodeableConcept>
</extension>
<extension url="value">
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="255372005"/>
</coding>
<text value="Variable"/>
</valueCodeableConcept>
</extension>
</extension>
<url value="https://fhir.nzf.org.nz/fhir/PlanDefinition/60071000210106"/>
<identifier>
<system value="http://snomed.info/sct"/>
<value value="60071000210106"/>
</identifier>
<version value="0.1.0"/>
<name
value="GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel"/>
<title
value="GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel"/>
<subtitle
value="Gynaecological Endometrial Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/>
<code value="clinical-protocol"/>
</coding>
</type>
<status value="active"/>
<date value="2022-10-28"/>
<publisher value="Te Aho o Te Kahu, Cancer Control Agency"/>
<description
value="A drug treatment regimen for Gynaecological Endometrial Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel"/>
<useContext>
<code>
<system
value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
<code value="focus"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="310789003"/>
</coding>
<text value="Gynaecological"/>
</valueCodeableConcept>
</useContext>
<useContext>
<code>
<system
value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
<code value="focus"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="93781006"/>
</coding>
<text value="Endometrial"/>
</valueCodeableConcept>
</useContext>
<copyright value="All rights reserved."/>
<approvalDate value="2022-10-28"/>
<lastReviewDate value="2022-10-28"/>
<author>
<name value="New Zealand Medicines Formulary LP"/>
</author>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/29449189"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/29449189"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/27397040"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/27397040"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/31345626"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/31345626"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641., PMID: 25089112"/>
<url value="https://pubmed.ncbi.nlm.nih.gov/25089112"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/25089112"/>
</document>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021)."/>
</relatedArtifact>
<relatedArtifact>
<type value="citation"/>
<display
value="Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020)."/>
</relatedArtifact>
<action id="6c16faca-cb95-4db6-ab7d-433b4d991532|10">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-child-regimen-extra-details">
<valueMarkdown
value="<p>Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy.</p>"/>
</extension>
<title value="Part 1: cISplatin chemoradiation"/>
<selectionBehavior value="all"/>
<definitionCanonical value="#6c16faca-cb95-4db6-ab7d-433b4d991532|10"/>
</action>
<action id="60f966e0-b24e-47fa-9e0c-d90abec4e58e|10">
<extension
url="http://hl7.org.nz/fhir/StructureDefinition/sact-child-regimen-extra-details">
<valueMarkdown
value="<p>Commence within 3 weeks after completion of radiation therapy.</p>"/>
</extension>
<title value="Part 2: cARBOplatin and PACLItaxel"/>
<selectionBehavior value="all"/>
<definitionCanonical value="#60f966e0-b24e-47fa-9e0c-d90abec4e58e|10"/>
</action>
</PlanDefinition>